曲唑酮治疗持续性疼痛性躯体形式障碍的双盲对照研究  

A DOUBLE-BLIND STUDY ON TRAZODONE IN THE TREATMENT OF PERSISTENT SOM-ATOFORM PAIN DISORDER

作　　者：王元秀[1] 任泽华[1] 王胜杰[1] 

机构地区：[1]山东省滨州市人民医院精神卫生中心,滨州256613

出　　处：《中国疼痛医学杂志》2003年第2期70-72,共3页Chinese Journal of Pain Medicine

摘　　要：目的:观察曲唑酮与止痛剂对持续性疼痛性躯体形式障碍的疗效与副反应。方法:140例患者随机分为2组进行双盲对照(每组70例),分别以曲唑酮或去痛剂布洛芬治疗4周。其疗效和副反应分别用汉密顿抑郁量表(HAMD)和临床疗效评定标准和副反应量表(TESS)评定。结果:曲唑酮的有效率大于布洛芬,分别是92.85％和62.85%(P<0.01);副反应发生率也大于布洛芬(P<0.01),但均较轻。结论:曲唑酮对持续性疼痛性躯体形式障碍疗效肯定,副反应轻。Objective: To observe the effects and side-effects of trazodone (TZD) and analgesic ibuprofen (PRF) in the treament of persistent somatoform pain disorder. Methods: One hundred and fouty patients were rendomly divided into two groups (70 patients in each). They were treated with TZD and PRF respectively for 4 weeks. The clinical effects and side-effects were double-blind evaluated by using HAMD and TESS respectively. Results; The effective rate of TZD and PRF were 92. 85% and 62. 85% respectively (P <0. 01). TZD also showed a side effects rate(P <0. 01) , including lethargy, nausea, anepi-thymia etc, but not serious. Conclusion: Trazodone is an effective and safe drug in the treatment of per-sistant somatoform pain disorders.

关 键 词：持续性疼痛性躯体形式障碍 曲唑酮 去痛剂 

分 类 号：R749.2[医药卫生—神经病学与精神病学]